Summary of the risk management plan

This is a summary of risk management plan (RMP) for Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets.

The RMP details important risks of Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets, how these risks can be minimised, and how more information will be obtained about Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg filmcoated tablets´s risks and uncertainties (missing information).

Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets´s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets should be used.

Important new concerns or changes to the current ones will be included in updates of
Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets.

I. The medicine and what it is used for

Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets is authorized for the treatment of adult patients with type 2 diabetes mellitus (see SmPC for the full indication). It contains Sitgliptin hydrochloride and Metformin hydrochloride as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg filmcoated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg filmcoated tablets together with measures to minimise such risks are outlined below.
Measures to minimise the risks identified for medicinal products can be:

•Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
•Important advice on the medicine's packaging;
•The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
•The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg filmcoated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg filmcoated tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken.

Important risks can be regarded as identified or potential.

Identified risks are concerns for which there is sufficient proof of a link with the use of Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets.

Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation.

Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine)

Tabla 03. Summary of Safety Concerns

Important Identified Risks	•Lactic acidosis
Important Potential Risks	•Pancreatic Cancer
Missing Information	•Exposure during pregnancy and lactation

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorization

There are no studies which are conditions of the marketing authorisation or specific obligation of Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/850 mg film-coated tablets; Sitagliptin hydrochloride & Metformin hydrochloride 50 mg/1000 mg film-coated tablets.